How to buy Ikena Oncology stock (Ikena Oncology)

Ikena Oncology is a biotechnology business based in the US. Ikena Oncology shares (IKNA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.71 – an increase of 1.18% over the previous week. Ikena Oncology employs 18 staff and has a trailing 12-month revenue of around $1.8 million.

Our top picks for where to buy Ikena Oncology stock

Buy Ikena Oncology stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ikena Oncology stock price (NASDAQ: IKNA)

Use our graph to track the performance of IKNA stocks over time.

Ikena Oncology shares at a glance

• Key figures

Information last updated 2024-10-24.

Latest market close	$1.71
52-week range	$1.02 - $4.63
50-day moving average more info button	$1.70
200-day moving average more info button	$1.56
Wall St. target price	$4.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.42

Is it a good time to buy Ikena Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ikena Oncology price performance over time

Historical closes compared with the close of $1.72 from 2024-10-25

1 week (2024-10-22)	1.78%
1 month (2024-09-30)	-0.58%
3 months (2024-07-30)	1.18%
6 months (2024-04-30)	30.30%

1 year (2023-10-30)	-54.13%
2 years (2022-10-28)	-37.45%
3 years (2021-10-29)	10.75
5 years (2019-10-26)	N/A

Ikena Oncology financials

Revenue TTM	$1.8 million
Gross profit TTM	$-48,703,000
Return on assets TTM	-27.41%
Return on equity TTM	-44.54%
Profit margin	0%
Book value	$2.96
Market Capitalization more info button	$81.6 million

TTM: trailing 12 months

Ikena Oncology share dividends

We're not expecting Ikena Oncology to pay a dividend over the next 12 months.

You may also wish to consider:

Ikena Oncology share price volatility

Over the last 12 months, Ikena Oncology's shares have ranged in value from as little as $1.02 up to $4.625. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ikena Oncology's is 0.491. This would suggest that Ikena Oncology's shares are less volatile than average (for this exchange).

To put Ikena Oncology's beta into context you can compare it against those of similar companies.

• Oncorus Inc (ONCR.US): 1.954
• Kura Oncology (KURA.US): 0.835
• AVROBIO (AVRO.US): 1.223

Ikena Oncology overview

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. .

Frequently asked questions

null
What percentage of Ikena Oncology is owned by insiders or institutions?
Currently 6.075% of Ikena Oncology shares are held by insiders and 78.484% by institutions. How many people work for Ikena Oncology?
Latest data suggests 18 work at Ikena Oncology. When does the fiscal year end for Ikena Oncology?
Ikena Oncology's fiscal year ends in December. Where is Ikena Oncology based?
Ikena Oncology's address is: 645 Summer Street, Boston, MA, United States, 02210 What is Ikena Oncology's ISIN number?
Ikena Oncology's international securities identification number is: US45175G1085